Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its novel injectable PLAT001, intended for the treatment of advanced or metastatic solid tumors, including pancreatic cancer.
PLAT001, a groundbreaking nanomedicine, is a polymer-coupled small molecule drug under development for the treatment of advanced or metastatic solid tumors. Preclinical efficacy studies have demonstrated that PLAT001 exhibits significant tumor inhibitory effects on animal models of pancreatic cancer and liver cancer, marking a promising step forward in the development of new cancer therapies.- Flcube.com
